Quantcast

Latest ViroPharma Incorporated Stories

2011-05-11 06:30:00

EXTON, Pa., May 11, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO)announced today that Halozyme has granted ViroPharma an exclusive worldwide license to use Halozyme's proprietary Enhanze(TM) technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) technology in combination with a C1 esterase inhibitor. Additionally, Halozyme has agreed not to grant to any third party rights to...

2011-05-11 06:29:00

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and ViroPharma Incorporated (Nasdaq: VPHM), today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development of a subcutaneous formulation of Cinryze (C1 esterase inhibitor [human]). Under terms of the agreement, Halozyme may receive up to $83 million, commencing with an upfront payment of $9 million and total potential...

2011-04-28 06:30:00

EXTON, Pa., April 28, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the first quarter ended March 31, 2011. In the first quarter of 2011, we: Achieved a record $127 million in net product sales, including $57 million in net sales of Cinryze® (C1 esterase inhibitor [human]) representing Cinryze growth of 62 percent over the same period in 2010; Attained non-GAAP adjusted net income of $45 million; GAAP net income...

2011-04-27 10:00:00

EXTON, Pa., April 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 36th Annual Healthcare Conference at 10:40 A.M. ET on Tuesday, May 3, 2011. The conference is being held at the InterContinental Hotel in Boston, MA. Vincent Milano, president and chief executive officer of ViroPharma, will present at the Bank of America/Merrill Lynch 2011...

2011-04-20 14:00:00

EXTON, Pa., April 20, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2011 are expected to be released on Thursday, April 28, 2011 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2011 first quarter financial results and other business. The press release and the live...

2011-03-29 09:54:00

EXTON, Pa., March 29, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 clinical study to evaluate the safety and efficacy of C1 Esterase Inhibitor [Human] for the treatment of acute antibody-mediated rejection (AMR) in recipients of donor-specific cross-match positive kidney transplants. This randomized, double blind, placebo-controlled study will evaluate the safety, tolerability and clinical effect of C1 Esterase Inhibitor [Human] for...

2011-03-22 09:19:00

EXTON, Pa., March 22, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced data presented in two poster presentations relating to Cinryze® (C1 esterase inhibitor [human]) at the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, March 18 through 22, in San Francisco, CA. Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in...

2011-03-21 08:20:00

EXTON, Pa., March 21, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the launch of "HAE and Me," an online community that unites teens and adults with hereditary angioedema (HAE) through shared experiences to help them better manage their disease. The website, www.HAEandMe.com, features information about HAE, video stories, and first-hand tips from patients, as well as expert advice about living with this rare and potentially life-threatening swelling...

2011-03-18 08:35:00

EXTON, Pa., March 18, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion at its plenary meeting in March 2011 recommending approval of a Centralized Marketing Authorization for Cinryze® (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention...

2011-03-09 06:30:00

EXTON, Pa., March 9, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company's Board of Directors has authorized the use of up to $150 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017. Purchases may be made by means of open market transactions, block transactions, privately negotiated purchase transactions or other techniques from time to time, as determined by ViroPharma's management, and in accordance...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.